Guardant Health Reports Strong Q1 Results, Raises Full-Year Revenue Guidance
Summary
Guardant Health announced robust first-quarter 2026 financial results, with revenue increasing 48% year-over-year, and significantly raised its full-year 2026 revenue guidance.
Key Events
-
Strong Q1 2026 Revenue Growth
Total revenue surged 48% year-over-year to $301.7 million, driven by strong performance in oncology and a more than 600% increase in screening revenue.
-
Raised Full-Year 2026 Revenue Guidance
The company increased its 2026 revenue guidance to a range of $1.30 to $1.32 billion, representing 32% to 34% growth, up from the prior range of $1.25 to $1.28 billion.
-
Improved Non-GAAP Net Loss
Non-GAAP net loss per share improved to $0.45 for Q1 2026, compared to $0.49 in the prior year period.
-
Operational Highlights
The quarter included FDA approval for Guardant360® CDx as a companion diagnostic and new collaborations to expand access to its Shield screening tests.
Analysis
Guardant Health's robust first-quarter performance, marked by a 48% year-over-year revenue increase and significant growth in its screening segment, demonstrates strong operational momentum. The decision to materially raise full-year revenue guidance signals management's increased confidence in sustained growth and market adoption of its oncology and screening tests. This positive financial update, following recent FDA approval for Guardant360® CDx, reinforces the company's strong market position and execution.
At the time of this filing, GH was trading at $95.08 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $12.1B. The 52-week trading range was $36.36 to $120.74. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.